Shantha Biotechnics
| Industry | Biotechnology, Vaccines |
|---|---|
| Founded | 1993 |
| Founder(s) | K I Varaprasad Reddy |
| Headquarters | Medchal, Hyderabad (India) |
| Key people |
K I Varaprasad Reddy Chairman of the Board, Harish Iyer, Chief Executive Officer |
| Products | recombinant DNA vaccines |
| Parent | Sanofi |
| Website | Shanthabiotech.com |
Shantha Biotechnics is an Indian biotechnology company based in Hyderabad. It is the first Indian company to develop, manufacture and market recombinant human healthcare products in India. The company is a wholly owned subsidiary of Sanofi group.[1]
History
The genesis of Shantha Biotechnics, Ltd. can be traced back to the initiatives of Dr. K I Varaprasad Reddy and Khalil Ahmed. Varaprasad and Ahmed established the company in 1993 to produce cost-effective drugs to reach the common man at an affordable price, while maintaining International standards in quality.[1] The project originated as an R&D outfit at the Osmania University under the industry-university interactive programme in 1993, and later operated out of the Center for Cellular and Molecular Biology until an independent R&D facility was built.
In 2009, the vaccine division of French pharmacological company Sanofi Pasteur acquired Hyderabad-based Shantha Biotechnics, which has been valued at euro 550 million (over Rs 3,770 crore).[2]
Products
Drugs developed by Shantha include SHANVAC-B, SHANFERON, SHANKINASE, SHANPOIETIN, SHANTETRA, SHAN5, SHAN HIB-DPT, SHAN HIB, and SHANTT.
Today, Shantha Biotechnics caters to major international markets including Asia-Pacific, Africa, CIS and Latin America in addition to international organisations like UNICEF and PAHO.
See also
References
- ↑ 1.0 1.1 "Shantha Biotech to launch 5-in-1 pediatric vaccine - CNBC-TV18". Moneycontrol.com. Retrieved 2012-09-28.
- ↑ Somashekar Mulugu. "Business Line : Companies News : Top level changes at Shantha Biotechnics". Thehindubusinessline.com. Retrieved 2012-09-28.
External links
- Sanofi Pasteur homepage.